March 15 (Reuters) - Orexigen Therapeutics Inc:
* Orexigen will retain regulatory affairs responsibilities
in EU countries
* Orexigen will supply Mysimba tablets to Valeant at an
agreed transfer price
* Orexigen Therapeutics announces commercialization and
distributorship agreement with Valeant Pharmaceuticals (NYSE:VRX) for
Mysimba (naltrexone hcl / bupropion hcl prolonged release) for
18 central and eastern european countries and Turkey
* Under terms of agreement, Valeant will be responsible for
commercialization activities in 19 countries
* Under terms of agreement, Valeant will be responsible for
obtaining regulatory approvals in non-EU countries
* Orexigen Therapeutics Inc says announced strategic
acquisition of all U.S. rights to Contrave
* Orexigen Therapeutics Inc says upon completion of
acquisition, Orexigen will own all rights to Contrave in nearly
all global territories
Source text for Eikon: ID:nPnc4vC4da
Further company coverage: OREX.O
(Bengaluru Newsroom +91 80 6749-1130; within U.S. +1 646 223
8780)